The other is a triple agonist
[1] [25] The kidneys contribute to overall homeostasis in the body, including carnitine levels
The choice here is critical, and we'll dive deeper into it in the next section
Last reviewed: April 21, 2026 Updated with Phase 3 TRIUMPH-4 data Primary sources: NEJM, Eli Lilly, ClinicalTrials.gov Retatrutide is a triple agonist (GLP-1 + GIP + glucagon) currently in Phase 3 trials, showing stronger early weight loss data
If done wrong, the drug might not work as well
However, during clinical translation, the structural complexity of the human liver, the heterogeneity of disease microenvironments, and interspecies differences often lead to suboptimal performance of nanodrugs in human trials despite promising results in preclinical animal studies